OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Alison M. Schram, Igor Odintsov, Madelyn Espinosa‐Cotton, et al.
Cancer Discovery (2022) Vol. 12, Iss. 5, pp. 1233-1247
Open Access | Times Cited: 117
Alison M. Schram, Igor Odintsov, Madelyn Espinosa‐Cotton, et al.
Cancer Discovery (2022) Vol. 12, Iss. 5, pp. 1233-1247
Open Access | Times Cited: 117
Showing 1-25 of 117 citing articles:
Therapeutic developments in pancreatic cancer
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 139
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 139
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 104
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 104
Emerging Targeted Therapies for HER2-Positive Breast Cancer
María F. Mercogliano, Sofía Bruni, Florencia Mauro, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1987-1987
Open Access | Times Cited: 81
María F. Mercogliano, Sofía Bruni, Florencia Mauro, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1987-1987
Open Access | Times Cited: 81
Recent progress in targeted therapy for non-small cell lung cancer
Yanxia Xiao, Pu Liu, Jie Wei, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 47
Yanxia Xiao, Pu Liu, Jie Wei, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 47
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 38
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 38
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque, et al.
Future Oncology (2024) Vol. 20, Iss. 16, pp. 1057-1067
Open Access | Times Cited: 22
Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque, et al.
Future Oncology (2024) Vol. 20, Iss. 16, pp. 1057-1067
Open Access | Times Cited: 22
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 21
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 21
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 18
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 18
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Alison M. Schram, Kōichi Goto, Dong-Wan Kim, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 6, pp. 566-576
Closed Access | Times Cited: 8
Alison M. Schram, Kōichi Goto, Dong-Wan Kim, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 6, pp. 566-576
Closed Access | Times Cited: 8
Patient‐derived xenograft model in cancer: establishment and applications
Ao Gu, Jiatong Li, Mengyao Li, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 6
Ao Gu, Jiatong Li, Mengyao Li, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 6
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 5
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 5
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 2
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 2
HER3 in cancer: from the bench to the bedside
Lucía Gandullo‐Sánchez, Alberto Ocaña, Atanasio Pandiella
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 55
Lucía Gandullo‐Sánchez, Alberto Ocaña, Atanasio Pandiella
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 55
Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry
Yeji Hong, Su-Min Nam, Aree Moon
Archives of Pharmacal Research (2023) Vol. 46, Iss. 3, pp. 131-148
Closed Access | Times Cited: 40
Yeji Hong, Su-Min Nam, Aree Moon
Archives of Pharmacal Research (2023) Vol. 46, Iss. 3, pp. 131-148
Closed Access | Times Cited: 40
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
If it’s a target, it’s a pan-cancer target: Tissue is not the issue
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 12
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 12
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
Qiuqiang Chen, Gang Jia, Xilin Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 10
Qiuqiang Chen, Gang Jia, Xilin Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 10
Fusion genes in pancreatic tumors
Αναστάσιος Γκουντάκος, Aatur D. Singhi, C. Benedikt Westphalen, et al.
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 430-443
Open Access | Times Cited: 10
Αναστάσιος Γκουντάκος, Aatur D. Singhi, C. Benedikt Westphalen, et al.
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 430-443
Open Access | Times Cited: 10
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Linyan Cheng, Lujun Chen, Yuan Shi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Linyan Cheng, Lujun Chen, Yuan Shi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes
Xinlin Liu, Yunlong Song, Panpan Cheng, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102826-102826
Closed Access | Times Cited: 9
Xinlin Liu, Yunlong Song, Panpan Cheng, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102826-102826
Closed Access | Times Cited: 9
Beyond HER2: Targeting the ErbB receptor family in breast cancer
Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, et al.
Cancer Treatment Reviews (2022) Vol. 109, pp. 102436-102436
Open Access | Times Cited: 32
Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, et al.
Cancer Treatment Reviews (2022) Vol. 109, pp. 102436-102436
Open Access | Times Cited: 32
Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
Molly Li, Kevin Mok, Tony Mok
Annals of Translational Medicine (2023) Vol. 11, Iss. 10, pp. 358-358
Open Access | Times Cited: 22
Molly Li, Kevin Mok, Tony Mok
Annals of Translational Medicine (2023) Vol. 11, Iss. 10, pp. 358-358
Open Access | Times Cited: 22
